Exact Sciences推出Cancerguard Test，这是一种新型的多种癌症早期检测血液测试，现已作为美国研究院开发的测试产品在美国上市，售价689美元

• Only MCED test on-market to analyze multiple biomarker classes, enhancing early cancer detection
• Offered as a laboratory-developed test at $689
• Nationwide access enabled through Quest Diagnostics' 7,000 patient access sites

The Cancerguard test delivered 68 percent sensitivity across six of the deadliest cancers and 64 percent overall sensitivity across a broader range of cancers, excluding breast and prostate, in test-development studies. It also found more than a third of stage I or II cancers, demonstrating its ability to detect disease when it's most treatable.1,2,4* Additionally, the test achieved high specificity of 97.4 percent, helping to minimize false positives and avoid unnecessary procedures.4 Modeling shows that over a 10-year period, use of Exact Sciences' MCED technology alongside current screening methods could reduce stage IV cancer diagnoses by 42 percent and lower overall cancer-related mortality by 18 percent.6 Together, these findings underscore the Cancerguard test's potential to meaningfully improve outcomes and elevate the standard of cancer detection.